Tiziana life sciences announces fda allowance for additional twenty patients to be enrolled in the intranasal foralumab multiple sclerosis expanded access program

New york, april 23, 2024 (globe newswire) -- tiziana life sciences, ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the u.s. food and drug administration (fda) has allowed its intranasal foralumab non-active secondary progressive multiple sclerosis (na-spms) expanded access (ea) program to expand from 10 patients to a total of 30 patients.
TLSA Ratings Summary
TLSA Quant Ranking